Europe CBIS pre clinical trials investigations have already been initiated......
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)-- Cannabis Science (NASD OTC: CBIS), a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges, is pleased to announce preclinical investigations being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi’s sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.
The company is entertaining entrance into a number of agreements with academic and private sector clinical research organizations that will facilitate initial studies to demonstrate scientific merit of CSTATI-1 and CS-S/BCC-1 that will predictably translate to human studies within the coming year, as clinical options for this patient population remain limited and the etiology of both aggressive squamous/basel cell carcinomas and Kaposi’s sarcoma is poor in immune compromised populations, comparative to other skin cancers.
“To match our U.S. efforts, we are aggressively pursuing institutional investigations abroad to take advantage of the significant expertise demonstrated in many academic research centers on cannabinoids to further our clinical investigation platform,” said Dr. Robert Melamede, President & CEO of Cannabis Science Inc., “we expect to generate from these collaborations a robust portfolio of preclinical data that supports the wide range of our scientific premises on the utility of cannabinoids for aggressive cancers for patients in desperate need of innovative clinical alternatives.”
The Company will update the public and its shareholders of the progress as peer-reviewed publication of the results of these preclinical investigations are made public.
About CS-S/BCC-1
Cannabis Science is currently working to develop preclinical investigations of CS-S/BCC-1 treatment of basal and squamous cell carcinomas.
About CS-TATI-1
Data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2). Funding for the Mount Sinai study was provided by a National Institutes of Health (NIH) Clinical and Translational Science Award Grant. Cannabis Science’s research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1’s, PO1’s and SBIRS which exist to support preclinical development of target validation and proof of concept studies. Cannabis Science will be pursing implementation of these studies through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European
News 
Market Data 
Discover 
